BR112014013495A2 - anticorpos para o receptor 3 do fator de crescimento epidérmico (her3) direcionados para o domínio iii e domíniuo iv de her3 - Google Patents
anticorpos para o receptor 3 do fator de crescimento epidérmico (her3) direcionados para o domínio iii e domíniuo iv de her3Info
- Publication number
- BR112014013495A2 BR112014013495A2 BR112014013495A BR112014013495A BR112014013495A2 BR 112014013495 A2 BR112014013495 A2 BR 112014013495A2 BR 112014013495 A BR112014013495 A BR 112014013495A BR 112014013495 A BR112014013495 A BR 112014013495A BR 112014013495 A2 BR112014013495 A2 BR 112014013495A2
- Authority
- BR
- Brazil
- Prior art keywords
- her3
- antibodies
- domain
- ligand
- fragments
- Prior art date
Links
- 102000001301 EGF receptor Human genes 0.000 title abstract 2
- 108060006698 EGF receptor Proteins 0.000 title abstract 2
- 230000008685 targeting Effects 0.000 title 1
- 239000003446 ligand Substances 0.000 abstract 8
- 239000012634 fragment Substances 0.000 abstract 6
- 230000001419 dependent effect Effects 0.000 abstract 4
- 230000019491 signal transduction Effects 0.000 abstract 4
- 125000000539 amino acid group Chemical group 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102000005962 receptors Human genes 0.000 abstract 2
- 108020003175 receptors Proteins 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161566912P | 2011-12-05 | 2011-12-05 | |
| PCT/IB2012/056956 WO2013084151A2 (en) | 2011-12-05 | 2012-12-04 | Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112014013495A8 BR112014013495A8 (pt) | 2017-06-13 |
| BR112014013495A2 true BR112014013495A2 (pt) | 2017-06-13 |
Family
ID=47561692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014013495A BR112014013495A2 (pt) | 2011-12-05 | 2012-12-04 | anticorpos para o receptor 3 do fator de crescimento epidérmico (her3) direcionados para o domínio iii e domíniuo iv de her3 |
Country Status (16)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3805268T3 (da) * | 2014-02-28 | 2025-01-20 | Merus Nv | Antistof, der binder erbb-2 og erbb-3 |
| US10844127B2 (en) | 2014-02-28 | 2020-11-24 | Merus N.V. | Antibodies that bind EGFR and ErbB3 |
| US20170291956A1 (en) | 2014-07-16 | 2017-10-12 | David Livingston | HER3 Inhibition in Low-grade Serous Ovarian Cancers |
| CN104530237B (zh) * | 2014-12-31 | 2017-09-05 | 百泰生物药业有限公司 | 抗Her1的治疗性抗体 |
| CA3002957A1 (en) | 2015-10-23 | 2017-04-27 | Koninklijke Nederlandse Akademie Van Wetenschappen | Binding molecules that inhibit cancer growth |
| JP6729926B2 (ja) * | 2016-05-12 | 2020-07-29 | 国立大学法人神戸大学 | ＥｒｂＢ３活性化に伴うシグナルの伝達抑制物質及びそのスクリーニング方法 |
| US11008402B2 (en) * | 2016-09-15 | 2021-05-18 | Universitat Stuttgart | Antigen binding protein against HER3 |
| KR101923641B1 (ko) * | 2016-11-25 | 2018-11-29 | 재단법인 목암생명과학연구소 | 항her3 항체 및 이를 포함하는 암 예방 또는 치료용 조성물 |
| EP3600413A1 (en) | 2017-03-31 | 2020-02-05 | Merus N.V. | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene |
| KR102744809B1 (ko) | 2017-05-17 | 2024-12-23 | 메뤼스 엔.페. | 유방암 치료를 위한 ErbB-2/ErbB-3 이중특이적 항체와 내분비 치료의 조합 |
| PL3665198T3 (pl) | 2017-08-09 | 2025-06-09 | Merus N.V. | Przeciwciała wiążące egfr i cmet |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR056857A1 (es) * | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| US8362215B2 (en) * | 2009-04-29 | 2013-01-29 | Trellis Bioscience, Llc | Antibodies immunoreactive with heregulin-coupled HER3 |
| PL2719708T3 (pl) * | 2009-11-13 | 2018-04-30 | Daiichi Sankyo Europe Gmbh | Materiał i sposoby leczenia lub zapobiegania chorobom związanym z HER-3 |
| US8481687B2 (en) * | 2010-04-09 | 2013-07-09 | Aveo Pharmaceuticals, Inc. | Anti-ErbB3 antibodies |
| TW201302793A (zh) * | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| US9346883B2 (en) * | 2011-05-13 | 2016-05-24 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Antibodies against HER3 |
| US10300140B2 (en) * | 2011-07-28 | 2019-05-28 | I2 Pharmaceuticals, Inc. | Sur-binding proteins against ERBB3 |
-
2012
- 2012-12-04 UY UY0001034488A patent/UY34488A/es not_active Application Discontinuation
- 2012-12-04 SG SG11201402784WA patent/SG11201402784WA/en unknown
- 2012-12-04 JP JP2014545420A patent/JP2015500830A/ja active Pending
- 2012-12-04 MX MX2014006731A patent/MX2014006731A/es unknown
- 2012-12-04 CN CN201280068966.8A patent/CN104093742A/zh active Pending
- 2012-12-04 IN IN4374CHN2014 patent/IN2014CN04374A/en unknown
- 2012-12-04 AU AU2012349739A patent/AU2012349739A1/en not_active Abandoned
- 2012-12-04 KR KR1020147018336A patent/KR20140099315A/ko not_active Withdrawn
- 2012-12-04 CA CA2857939A patent/CA2857939A1/en not_active Abandoned
- 2012-12-04 EP EP12816130.4A patent/EP2788381A2/en not_active Withdrawn
- 2012-12-04 BR BR112014013495A patent/BR112014013495A2/pt not_active Application Discontinuation
- 2012-12-04 TW TW101145508A patent/TW201331225A/zh unknown
- 2012-12-04 EA EA201491120A patent/EA201491120A1/ru unknown
- 2012-12-04 WO PCT/IB2012/056956 patent/WO2013084151A2/en not_active Ceased
- 2012-12-05 AR ARP120104559A patent/AR089085A1/es unknown
-
2014
- 2014-06-02 IL IL232950A patent/IL232950A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014013495A8 (pt) | 2017-06-13 |
| CN104093742A (zh) | 2014-10-08 |
| TW201331225A (zh) | 2013-08-01 |
| WO2013084151A2 (en) | 2013-06-13 |
| SG11201402784WA (en) | 2014-06-27 |
| MX2014006731A (es) | 2015-06-04 |
| EA201491120A1 (ru) | 2015-07-30 |
| AR089085A1 (es) | 2014-07-30 |
| JP2015500830A (ja) | 2015-01-08 |
| IL232950A0 (en) | 2014-07-31 |
| WO2013084151A3 (en) | 2014-01-03 |
| CA2857939A1 (en) | 2013-06-13 |
| EP2788381A2 (en) | 2014-10-15 |
| KR20140099315A (ko) | 2014-08-11 |
| UY34488A (es) | 2013-07-31 |
| AU2012349739A1 (en) | 2014-06-26 |
| IN2014CN04374A (cg-RX-API-DMAC7.html) | 2015-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014013495A8 (pt) | anticorpos para o receptor 3 do fator de crescimento epidérmico (her3) direcionados para o domínio iii e domíniuo iv de her3 | |
| BR112014013568A8 (pt) | anticorpos para o receptor do fator de crescimento epidermal 3 (her3) direcionados para o domínio ii do her3 | |
| BR112012024713A2 (pt) | "anticorpo humanizado, anticorpo monoclonal humanizado ou fragmento de anticorpo, seus usos, polinucleotídeo isolado, e composição farmacêutica" | |
| CL2012003093A1 (es) | Anticuerpo aislado multivalente que tiene al menos dos dominios de union a receptores para dos diferentes sitios de union de un receptor diana lrp6 que inhiben una via canonica de transduccion de señal wnt; anticuerpo aislado biparatopico que une lrp6; acido nucleico que lo codifica; vector que comprende dicho acido nucleico; composicion farmaceutica que comprende un anticuerpo multivalente anti-lrp6; metodo de obtencion de dicho anticuerpo; y su uso para tratar cancer. | |
| HRP20090213A2 (hr) | Postupak i međuprodukti u pripravi inhibitora integraze | |
| MX356218B (es) | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5. | |
| BR112014006390A2 (pt) | anticorpos, domínios variáveis e cadeias feitos especialmente para uso humano | |
| PH12012500881A1 (en) | Antibodies binding preferentially human csf1r extracellular domain 4 and their use | |
| WO2008121615A3 (en) | Antibody formulation | |
| BR112014011594A2 (pt) | anticorpos anti-il-36r | |
| WO2011119979A3 (en) | Antibodies to muc16 and methods of use thereof | |
| PH12013500333A1 (en) | Antibodies for epidermal growth factor receptor 3 (her3) | |
| AU2018256540A1 (en) | Novel asphalt binder additive compositions and methods of use | |
| BR112012008385A2 (pt) | inibidores de p13 cinase e uso dos mesmos. | |
| EA201390813A1 (ru) | Антитела и их применение | |
| BR112014015111A2 (pt) | composições e processos para anticorpos que se direcionam ao fator p | |
| BRPI0911332A2 (pt) | composições e uso de inibidores de epas1 | |
| BR112015006060A2 (pt) | agentes de ligação kir3dl2 | |
| MX374826B (es) | Un anticuerpo biespecífico que se une a pcrv y psl de pseudomonas. | |
| PL2013236T3 (pl) | Przeciwciała łączące się z zewnątrzkomórkową domeną receptora kinazy tyrozynowej ALK | |
| AU2011217848A8 (en) | Integrin aVB8 neutralizing antibody | |
| BR112016008644A2 (pt) | Inibidor de dinamina 2 para uso no tratamento de uma miopatia centronuclear; método para identificar ou triar moléculas úteis no tratamento de uma miopatia centronuclear, de preferência, xlcnm; e composição farmacêutica | |
| UA106529C2 (uk) | Гуманізоване антитіло до cxcr4 для лікування раку | |
| PH12013500616A1 (en) | Antibody compositions and methods of use | |
| BR112013031943A2 (pt) | "proteínas e anticorpos contra g-csfr, composição que os compreendem e uso dos mesmos". |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |